Limit drug replacement dosage forms or specifications inflated price prices have doubled

Business Club Nov. 15th From the 13th to the 14th, the Fifth China Growth Pharmaceutical Business Development Forum was held in Wuhan. The relevant person in charge of the Drug Development Review Center of the National Development and Reform Commission “fights” to the participating pharmaceutical companies: The new round of drug price reform will “inhibit unreasonable price increases in circulation” and focus on cracking down on price changes in prescriptions or specifications for drug replacements. behavior.

Since the implementation of policies such as the Basic Drug Directory, it can be said that "there are policies and countermeasures." In response to the government's policy of limiting the prices of essential medicines, medical insurance products, special drugs, and monopoly drugs, some companies circumvent the national price restrictions by changing the "vetts" of pharmaceutical dosage forms and specifications in actual operations. For example, a limited-edition tablet medicine “transform” capsule is not on the monitoring list and can be marketed on its own, and the price may be doubled.

This policy loophole is expected to be blocked in the new Drug Price Management Measures. It has been revealed that the new drug pricing method will issue a price comparison rule for drug formulations and specifications. Regardless of how a drug is transformed, drug prices are within the scope of supervision.